Evidence map›Paper›PMID 32257061›Full record

ArticleAuto- immunity highlights2019

A new M23-based ELISA assay for anti-aquaporin 4 autoantibodies: diagnostic accuracy and clinical correlation.

Marilina Tampoia, Letizia Abbracciavento, Giuseppina Barberio, Martina Fabris, Nicola Bizzaro, Study Group on Autoimmune Diseases of the Italian Society of Clinical Pathology and Laboratory Medicine, Italy

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Auto- immunity highlights, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marilina Tampoia1Clinical Pathology Laboratory, Polyclinic of Bari, Department of Biomedical Sciences and Human Oncology, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Letizia Abbracciavento1Clinical Pathology Laboratory, Polyclinic of Bari, Department of Biomedical Sciences and Human Oncology, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Giuseppina Barberio2Laboratory Medicine, Department of Clinical Pathology, Treviso Hospital, Treviso, Italy.
Martina Fabris3Laboratory of Immunopathology and Allergology, University Hospital Udine, P.le S. Maria della Misericordia 15, 33100 Udine, Italy.
Nicola Bizzaro4Laboratory of Clinical Pathology, San Antonio Hospital, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
Study Group on Autoimmune Diseases of the Italian Society of Clinical Pathology and Laboratory Medicine, Italy
University of Bari Aldo Moro · ITCa' Foncello Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlthough many assays have been developed to detect anti-aquaporin-4 (AQP4) antibodies, most of these assays require sophisticated techniques and are thus only available at specialized laboratories. The aim of this study was to evaluate the analytical and clinical performance of a new commercial enzyme-linked immunosorbent assay (ELISA RSR, AQP4 Ab Version 2) to detect anti-AQP4 antibodies performed on a fully automated system (SkyLAB 752).

methodsSerum samples from 64 patients with neuromyelitis optica spectrum disorders (NMOSD) (including NMO, longitudinally extensive myelitis-LETM, optical neuritis and myelitis) and 27 controls were tested for anti-AQP4 antibodies. All sera were previously tested using an indirect immunofluorescence (IIF) method on primate tissue, as the reference method. Commercial control sera were used to determine within-run, between-day and within-laboratory precision (CLSI guidelines).

resultsAt a cut-off value of 2.1 U/mL as determined by ROC curves, sensitivity and specificity for NMO were 83.3% and 100%, respectively. The ELISA assay provided 100% concordant results with the reference IIF method. The median concentration of anti-AQP4 antibodies was statistically higher in patients with NMO than in patients with LETM (

conclusionsThis new ELISA method performed on a fully automated system, showed high sensitivity and absolute specificity, good CV in precision tests, and provided observer-independent quantitative results.

Indexed as

Analytical imprecisionAnti-AQP4 autoantibodiesEnzyme-linked immunosorbent assayNMO spectrum disorders

Identifiers

PMID32257061
PMCPMC7065340
OpenAlexW2952870485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.